

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

### PIGF-based testing to help diagnose suspected pre-eclampsia (update of DG23)

#### Stakeholder list

##### **Manufacturers**

PerkinElmer Health Sciences  
Quidel Ireland  
Roche Diagnostics Ltd  
Thermo Fisher Scientific

##### **Professional groups**

British Maternal & Fetal Medicine Society  
Royal College of Obstetricians and Gynaecologists  
Royal College of Physicians  
The Renal Association  
The Royal College of Midwives

##### **Patient/carers groups**

Action on Pre-eclampsia (APEC)  
AIMS - Association for Improvements in the Maternity Services  
Birth Trauma Association

##### **External Assessment Group**

Southampton Health Technology Assessments Centre

##### **Others**

Department of Health  
Healthcare Improvement Scotland  
Medicines and Healthcare products Regulatory Agency  
Welsh Government

##### **Specialist Committee Member applicants**

**Definitions:****Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

**External Assessment Group (EAG)**

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technologies.